GlobeNewswire Inc.··NaLBL-047 Advances to Clinical Testing for Autoimmune Diseases as Dianthus Raises $719M
Nanjing Leads Biolabs and Dianthus Therapeutics advance LBL-047, a bifunctional fusion protein, into Phase 1 trials for three autoimmune conditions with $719M in funding.
DNTHclinical developmentautoimmune disease